NEW YORK (GenomeWeb News) – Agilent Technologies and Molecular Discovery on Sunday announced a co-marketing agreement to provide an advanced metabolite identification platform to biopharmaceutical researchers.

Under the terms of the deal, Agilent's high-resolution liquid chromatography/mass spectrometry technology will be co-marketed with Molecular Discovery's Mass-MetaSite software "to enable superior identification and analysis of complex biological mixtures," the firms said in a joint statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.